Kezar Life Sciences, Inc. (KZR)
2025-06-30 | 2024-09-30 | |||
|---|---|---|---|---|
| Interest income | - | 2,038 | ||
| Interest expense | - | 403 | ||
| Restructuring and impairment charges | - | - | ||
| Research and development | 9,583 | 16,242 | ||
| General and administrative | 5,016 | 5,706 | ||
| Total operating expenses | 14,599 | 21,948 | ||
| Loss from operations | -14,599 | -21,948 | ||
| Interest income | 1,197 | - | ||
| Interest expense | 302 | - | ||
| Net loss | -13,704 | -20,313 | ||
| Net loss per common share, basic (in dollars per share) | -1.87 | -2.78 | ||
| Net loss per common share, diluted (in dollars per share) | -1.87 | -2.78 | ||
| Weighted-average shares used to compute net loss per common share, basic (in shares) | 7,311,032 | 7,296,222 | ||
| Weighted-average shares used to compute net loss per common share, diluted (in shares) | 7,311,032 | 7,296,222 | ||